More trouble for Ranbaxy: FDA bans drugs from Toansa facility
This article was originally published in Scrip
Executive Summary
Ranbaxy's insistence earlier this month it was working to improve its systems and processes and was "fully committed to upholding the highest standards" after the FDA found deficiencies at another of the company's plants was not enough assurance to stop US regulators on 23 January from now banning products from that facility.